Search results for "MDR"

showing 5 items of 35 documents

Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis

2015

Outcomes from 5 years of treatment with agalsidase alfa enzyme replacement therapy (ERT) for Fabry disease in patients enrolled in the Fabry Outcome Survey (FOS) were compared with published findings for untreated patients with Fabry disease. Data were extracted from FOS, a Shire-sponsored database, for comparison with data from three published studies. Outcomes evaluated were the annualized rate of change in estimated glomerular filtration rate (eGFR) and left ventricular mass indexed to height (LVMI) as well as time to and ages at a composite morbidity endpoint and at death. FOS data were extracted for 740 treated patients who were followed for a median of ~ 5 years. Compared with no trea…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismUrologyCardiomyopathyRenal functionSE Standard errorLeft ventricular hypertrophyBiochemistryLVH Left ventricular hypertrophyLong-term effectivenessEndocrinologyGeneticsMedicineMDRD Modification of Diet in Renal Diseaselcsh:QH301-705.5Molecular BiologyAgalsidase alfaeGFR Estimated glomerular filtration rateFabry diseaselcsh:R5-920CI Confidence intervalbusiness.industryEnzyme replacement therapymedicine.diseaseEgfr Estimated glomerular filtration rateFabry diseaseSurgeryARB Angiotensin receptor blockerSEM Standard error of the meanStandard errorlcsh:Biology (General)SI:TherapyEnzyme replacement therapyCohortFOS Fabry Outcome SurveyLVMI Left ventricular mass indexed to heightlcsh:Medicine (General)businessACEI Angiotensin-converting enzyme inhibitorAgalsidase alfaERT Enzyme replacement therapyMolecular Genetics and Metabolism Reports
researchProduct

Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy

2016

ABSTRACT Objective: To evaluate the cost-effectiveness of bedaquiline plus background drug regimens (BR) for multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) in Italy. Methods: A Markov model was adapted to the Italian setting to estimate the incremental cost-effectiveness ratio (ICER) of bedaquiline plus BR (BBR) versus BR in the treatment of MDR-TB and XDR-TB over 10 years, from both the National Health Service (NHS) and societal perspective. Cost-effectiveness was evaluated in terms of life-years gained (LYG). Clinical data were sourced from trials; resource consumption for compared treatments was modelled according to advice from an expert c…

medicine.medical_specialtyPediatricsTuberculosisCost effectivenessBedaquilinelcsh:Business03 medical and health scienceschemistry.chemical_compound0302 clinical medicineSocietal perspectivemedicineOriginal Research Article030212 general & internal medicineResource consumptionSensitivity analysescost-effectivenessDisease treatmenthealth care economics and organizationsbusiness.industrylcsh:Public aspects of medicinelcsh:RA1-1270medicine.diseaseNational health serviceMDR tuberculosis030228 respiratory systemchemistryItalyEmergency medicineXDR tuberculosisOriginal ArticleBedaquilinebusinesslcsh:HF5001-6182Journal of Market Access & Health Policy
researchProduct

Bloodstream infections in intensive care unit patients: Distribution and antibiotic resistance of bacteria

2015

Vincenzo Russotto,1 Andrea Cortegiani,1 Giorgio Graziano,2 Laura Saporito,2 Santi Maurizio Raineri,1 Caterina Mammina,2 Antonino Giarratano1 1Department of Biopathology and Medical Biotechnologies (DIBIMED), Section of Anaesthesia, Analgesia, Intensive Care and Emergency, Paolo Giaccone University Hospital, University of Palermo, Palermo, Italy; 2Department of Sciences for Health Promotion and Mother-Child Care, University of Palermo, Palermo, Italy Abstract: Bloodstream infections (BSIs) are among the leading infections in critically ill patients. The case-fatality rate associated with BSIs in patients admitted to intensive care units (ICUs) reaches 35%–50%. The emergence and diffusi…

medicine.medical_specialtybloodstream infectionsmedicine.drug_classAntibioticsICU; MDR; antibiotic; bloodstream infections; intensive care unit; multidrug resistantSettore MED/41 - AnestesiologiaReviewBloodstream infectionmedicine.disease_causelcsh:Infectious and parasitic diseaseslaw.inventionAntibiotic resistancelawIntensive careEpidemiologyMDRmedicinelcsh:RC109-216Pharmacology (medical)Intensive care unitMED/41 - ANESTESIOLOGIAIntensive care medicinePharmacologybiologybusiness.industryAntibioticAcinetobacterbiology.organism_classificationIntensive care unitMultiple drug resistanceInfectious DiseasesMultidrug resistantStaphylococcus aureusICUAntibiotic; Bloodstream infections; ICU; Intensive care unit; MDR; Multidrug resistantbusiness
researchProduct

Ar novecošanos saistītu biomarķieru un mtDNS mutāciju izpēte multirezistentās tuberkulozes pacientiem

2020

Darba mērķis: izmantojot biomarķierus, noteikt iespējamo multirezistentās tuberkulozes (MDR-TB) infekcijas saistību ar imūnsistēmas novecošanos un noskaidrot mtDNS variāciju lomu slimības gaitā un farmakoterapijā. Darbā ir analizētas mtDNS daudzuma un telomēru garuma izmaiņas, un apskatīta MDR-TB pacientu ieradumu un citu saistīto faktoru ietekme. MDR-TB pacientiem konstatēts paaugstināts mtDNS kopiju skaits un samazināts telomēru garums salīdzinājumā ar kontroles grupu. Būtiskās izmaiņas vērojamas tikai vīriešu grupā. Biomarķieru izmaiņas iespaidoja arī smēķēšana, terapijas ilgums un saņemto zāļu devu skaits. Identificētas vairākas mtDNS variācijas ar iespējamo ietekmi uz slimības procesie…

telomēru garumsrelatīvais mtDNS daudzumsMDR-TBBioloģijamtDNS variācijasimunosenescence
researchProduct

SORVEGLIANZA DELLE COLONIZZAZIONI DA STAPHYLOCOCCUS AUREUS METICILLINO-RESISTENTE E GRAM-NEGATIVI MULTI-RESISTENTI NELLE UNITA’ DI TERAPIA INTENSIVA …

2014

INTRODUZIONE: La diffusione della resistenza batterica, sia in ospedale che in comunità, costituisce un serio motivo di allarme. La disseminazione di microrganismi resistenti in ospedale, particolarmente accentuata in reparti critici quali le terapie intensive, è favorita oltre che dall’uso dei farmaci antimicrobici, da procedure chirurgiche e/o invasive, dalla presenza di pazienti compromessi e dal trasferimento da una struttura sanitaria ad un’altra di pazienti colonizzati o infetti. Una conoscenza dettagliata dell’entità del fenomeno e dei principali microrganismi antibiotico-resistenti in ambito nosocomiale è essenziale per lo sviluppo di strategie volte a prevenire tale fenomeno. In qu…

terapia intensiva neonataleantibiotico-resistenzaSettore MED/38 - Pediatria Generale E SpecialisticaUTINStaphylococcus aureuSettore MED/42 - Igiene Generale E ApplicataMRSA MDRGN
researchProduct